Loading clinical trials...
Loading clinical trials...
An Open Label, Dose-escalation Study to Evaluate Safety, Pharmacokinetics and Tumor Growth Control Rate of RO5083945, a Glycoengineered Antibody Against EGFR, in Patients With Metastatic and/or Locally Advanced Malignant EGFR+ Solid Tumors.
Conditions
Interventions
RO5083945
Locations
5
France
Toulouse, France
Villejuif, France
Barcelona, Barcelona, Spain
Seville, Sevilla, Spain
Valencia, Valencia, Spain
Start Date
June 1, 2008
Primary Completion Date
June 1, 2011
Completion Date
June 1, 2011
Last Updated
November 2, 2016
NCT07159659
NCT07169851
NCT00026884
NCT07213804
NCT06662786
NCT07191730
Lead Sponsor
Hoffmann-La Roche
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions